| Williams Energy Marketing & Trading | Devon Energy | oil and gas | price-fixing or anti-competitive practices | 2002 | $417,000,000 |
| ZF TRW Automotive Holdings Corp. | ZF Friedrichshafen | automotive parts | price-fixing or anti-competitive practices | 2016 | $183,750 |
| Zurich American Insurance Company | Zurich Insurance | financial services | price-fixing or anti-competitive practices | 2006 | $171,700,000 |
| Vyera Pharmaceuticals, LLC and Phoenixus AG | | | price-fixing or anti-competitive practices | 2021 | $40,000,000 |
| Indivior Inc. | Indivior PLC | pharmaceuticals | price-fixing or anti-competitive practices | 2023 | $102,500,000 |
| BP | BP | oil and gas | oil spill | 2015 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,900,000,000 |
| MOEX Offshore 2007 LLC | Mitsui | diversified | oil spill | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $25,000,000 |
| Abbott Laboratories | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $339,148,643 |
| Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $14,750,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $612,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | $71,000,000 |
| AstraZeneca Pharmaceuticals | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | $68,500,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | $13,500,000 |
| Boehringer-Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $95,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2016 | $19,500,000 |
| CareFusion | Becton Dickinson | medical equipment and supplies | off-label or unapproved promotion of medical products | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $40,100,000 |
| Celgene Corp. | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
| Cephalon Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $116,000,000 |
| Eisai Inc. | Eisai | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,658,249 |
| Elan Corp. | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $43,399,040 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | $62,000,000 |
| Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
| Genentech Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2000 | $19,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
| Healthpoint Ltd. | | | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $28,000,000 |
| Inspire Pharmaceuticals | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
| InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,700,000 |
| ISTA Pharmaceuticals, Inc. | Bausch Health | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $390,253 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | $181,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
| Medicis Pharmaceutical Corporation | Bausch Health | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,000,000 |
| Merck Sharp & Dohme Corp. | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $88,258,694 |
| Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $29,000,000 |
| Novo Nordisk Inc. | Novo Holdings A/S | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,574,209 |
| Organon | Organon & Co. | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | $31,000,000 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
| Otsuka American Pharmaceutical Inc. | Otsuka Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,700,000 |
| Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
| Pfizer | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | $35,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | $60,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | $42,900,000 |
| Purdue Pharma | Purdue Pharma | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | $19,500,000 |
| Schering-Plough Corporation | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $91,602,000 |
| Serono Inc. | Merck KGaA (EMD) | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $262,000,000 |
| Shire Pharmaceuticals LLC | Takeda Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,786,034 |
| UCB Inc. | UCB | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $9,893,322 |
| Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
| McKinsey & Company | McKinsey | business services | off-label or unapproved promotion of medical products | 2021 | $573,000,000 |
| Indivior plc | Indivior PLC | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | $300,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | $5,000,000,000 |
| Cardinal Health Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2021 | $6,489,000,000 |
| AmerisourceBergen Corporation | AmerisourceBergen | wholesalers | off-label or unapproved promotion of medical products | 2021 | $6,510,000,000 |
| McKesson Corporation | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2021 | $8,001,000,000 |
| Endo International plc | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $450,000,000 |
| Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $2,370,000,000 |
| Teva Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $4,250,000,000 |
| Walmart Stores | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | $3,100,000,000 |
| Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2022 | $5,700,000,000 |
| CVS | CVS Health | retailing | off-label or unapproved promotion of medical products | 2022 | $5,000,000,000 |
| Walmart | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | $8,500,000 |
| Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $8,200,000 |
| Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | $4,800,000 |
| Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2023 | $1,370,000,000 |
| Publicis Health | | | off-label or unapproved promotion of medical products | 2024 | $350,000,000 |
| Hikma Pharmaceuticals | Hikma Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | $150,000,000 |
| Ford Motor Company | Ford Motor | motor vehicles | motor vehicle safety violation | 2002 | $51,500,000 |
| General Motors Company | General Motors | motor vehicles | motor vehicle safety violation | 2017 | $120,000,000 |
| Toyota Motor Company | Toyota | motor vehicles | motor vehicle safety violation | 2013 | $29,000,000 |
| Ally Financial | Ally Financial | financial services | mortgage abuses | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $109,628,425 |
| Bank of America | Bank of America | financial services | mortgage abuses | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,382,415,075 |
| Bank of America Corporation | Bank of America | financial services | mortgage abuses | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $943,000,000 |
| Citigroup | Citigroup | financial services | mortgage abuses | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $413,041,577 |
| Countrywide Financial Corporation | Bank of America | financial services | mortgage abuses | 2010 | $3,004,100,000 |
| Countrywide Home Loans | Bank of America | financial services | mortgage abuses | 2008 | $8,680,000,000 |
| First Alliance Mortgage Company | | | mortgage abuses | 2002 | $60,000,000 |
| Household Finance Corp. | HSBC | financial services | mortgage abuses | 2002 | $484,000,000 |
| HSBC | HSBC | financial services | mortgage abuses | 2016 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $59,500,000 |
| JPMorgan Chase | JPMorgan Chase | financial services | mortgage abuses | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,121,188,661 |
| Lender Processing Services, Inc. | | | mortgage abuses | 2013 | $120,000,000 |
| Ocwen Financial Services | Ocwen Financial | financial services | mortgage abuses | 2013 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $127,300,000 |
| PHH Mortgage Corp. | Ocwen Financial | financial services | mortgage abuses | 2018 | $45,000,000 |
| SunTrust Mortgage Inc. | Truist Financial | financial services | mortgage abuses | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $40,000,000 |
| Wells Fargo | Wells Fargo | financial services | mortgage abuses | 2012 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,005,233,716 |
| ACI Worldwide | | | mortgage abuses | 2023 | $10,000,000 |
| Mattel, Inc. | Mattel | miscellaneous manufacturing | lead violation | 2008 | $12,000,000 |
| AbbVie Inc. | AbbVie | pharmaceuticals | kickbacks and bribery | 2018 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,800,000 |
| Ameritox Ltd. | | | kickbacks and bribery | 2010 | $814,000 |
| BioScrip, Inc. | Option Care Health | healthcare services | kickbacks and bribery | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,310,000 |
| Caremark | CVS Health | retailing | kickbacks and bribery | 2008 | $41,000,000 |
| DaVita Healthcare Partners | UnitedHealth Group | healthcare services | kickbacks and bribery | 2015 | $22,356,143 |
| GlaxoSmithKline, LLC | GlaxoSmithKline | pharmaceuticals | kickbacks and bribery | 2014 | $105,000,000 |
| Kos Pharmaceuticals | AbbVie | pharmaceuticals | kickbacks and bribery | 2010 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,454,432 |
| Medtronic | Medtronic | medical equipment and supplies | kickbacks and bribery | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $362,362 |
| Medtronic | Medtronic | medical equipment and supplies | kickbacks and bribery | 2014 | $327,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $83,129,754 |
| Omnicare | CVS Health | retailing | kickbacks and bribery | 2014 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,190,000 |
| Omnicare Inc. | CVS Health | retailing | kickbacks and bribery | 2016 | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $28,125,000 |
